NCT05283109View on ClinicalTrials.gov

ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

April 11, 2025

Study Completion Date

February 29, 2028

Conditions
Glioma, Malignant
Interventions
BIOLOGICAL

Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine

Vaccine that includes 3 peptides (EphA2 linked to P30 peptide, pp65 linked to P30 peptide, and Survivin linked to P30 peptide)

DRUG

Hiltonol

Hiltonol® is made up of synthetic (manmade) RNA (ribonucleic acid) and is used as an adjuvant to the vaccine, meaning it is used with the vaccine to stimulate or enhance the activation of your immune system.

Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center at Duke University, Durham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mustafa Khasraw, MBChB, MD, FRCP, FRACP

OTHER

NCT05283109 - ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM | Biotech Hunter | Biotech Hunter